Santen Pharmaceutical Co., Ltd. 4536
TSE · Japan · Health Technology
¥1,694.50+7.50 (+0.44%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL)Secures scalable commercial IOL manufacturing capacity for its Phase 3 lead product candidate, the BIM-IOL SystemAccelerates pathway to adding premium lens options into its IOL-based drug delivery systemSpyGlass Pharma intends to continue supporting AVS customers and licensees utilizing their proprietary IOL
Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.’s (“Santen”) Ryj
Recent performance snapshot Santen Pharmaceutical (TSE:4536) has been on investors radar after recent share price moves, with the stock showing positive returns over the past week, month and past 3 months. See our latest analysis for Santen Pharmaceutical. Beyond the recent gains, Santen Pharmaceutical’s 1-year total shareholder return of 24.35% and 3-year total shareholder return of 67.40% point to building momentum. The latest share price of ¥1,787 keeps attention on how expectations around...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.